Sarah E Tom1, Emerson M Wickwire2, Yujin Park1, Jennifer S Albrecht3. 1. Pharmaceutical Health Services Research Department, University of Maryland School of Pharmacy, Baltimore, Maryland. 2. Departments of Psychiatry and Medicine, University of Maryland School of Medicine, Baltimore, Maryland. 3. Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore, Maryland.
Abstract
STUDY OBJECTIVES: The objective of this study was to test the hypothesis that use of zolpidem, eszopiclone, and zaleplon would be associated with increased risk of traumatic brain injury (TBI) and hip fracture. METHODS: We conducted a case-crossover study on a 5% random sample of Medicare beneficiaries age 65 y or older hospitalized with either TBI (n = 15,031) or hip fracture (n = 37,833) during 2007-2009. Use of zolpidem, eszopiclone, or zaleplon during the 30-day period prior to injury hospitalization was compared to use during four control periods at 3, 6, 9, and 12 mo prior to injury. The primary outcome was hospitalization for TBI or hip fracture. RESULTS: Zolpidem use during the month prior to injury was associated with increased risk of TBI (odds ratio [OR] 1.87; 95% confidence interval [CI] 1.56, 2.25); however, eszopiclone use during the same period was not associated with increased risk (OR 0.67; 95% CI 0.40, 1.13). Zolpidem use during the month prior to injury was associated with increased risk of hip fracture (OR 1.59; 95% CI 1.41, 1.79); however, eszopiclone use during the same period was not associated with increased risk (OR 1.12; 95% CI 0.83, 1.50). Analysis of zaleplon use in the month prior to injury was limited by low drug utilization but was not associated with increased risk of TBI (OR 0.85; 95% CI 0.21, 3.34) or hip fracture (OR 0.92; 95% CI 0.40, 2.13) in this study. CONCLUSIONS: For the treatment of insomnia in older adults, eszopiclone may present a safer alternative to zolpidem, in terms of fall-related injuries.
STUDY OBJECTIVES: The objective of this study was to test the hypothesis that use of zolpidem, eszopiclone, and zaleplon would be associated with increased risk of traumatic brain injury (TBI) and hip fracture. METHODS: We conducted a case-crossover study on a 5% random sample of Medicare beneficiaries age 65 y or older hospitalized with either TBI (n = 15,031) or hip fracture (n = 37,833) during 2007-2009. Use of zolpidem, eszopiclone, or zaleplon during the 30-day period prior to injury hospitalization was compared to use during four control periods at 3, 6, 9, and 12 mo prior to injury. The primary outcome was hospitalization for TBI or hip fracture. RESULTS:Zolpidem use during the month prior to injury was associated with increased risk of TBI (odds ratio [OR] 1.87; 95% confidence interval [CI] 1.56, 2.25); however, eszopiclone use during the same period was not associated with increased risk (OR 0.67; 95% CI 0.40, 1.13). Zolpidem use during the month prior to injury was associated with increased risk of hip fracture (OR 1.59; 95% CI 1.41, 1.79); however, eszopiclone use during the same period was not associated with increased risk (OR 1.12; 95% CI 0.83, 1.50). Analysis of zaleplon use in the month prior to injury was limited by low drug utilization but was not associated with increased risk of TBI (OR 0.85; 95% CI 0.21, 3.34) or hip fracture (OR 0.92; 95% CI 0.40, 2.13) in this study. CONCLUSIONS: For the treatment of insomnia in older adults, eszopiclone may present a safer alternative to zolpidem, in terms of fall-related injuries.
Authors: Alon Y Avidan; Brant E Fries; Mary L James; Kristina L Szafara; Glenn T Wright; Ronald D Chervin Journal: J Am Geriatr Soc Date: 2005-06 Impact factor: 5.562
Authors: Katie L Stone; Terri L Blackwell; Sonia Ancoli-Israel; Jane A Cauley; Susan Redline; Lynn M Marshall; Kristine E Ensrud Journal: J Am Geriatr Soc Date: 2014-01-15 Impact factor: 5.562
Authors: Katie L Stone; Sonia Ancoli-Israel; Terri Blackwell; Kristine E Ensrud; Jane A Cauley; Susan Redline; Teresa A Hillier; Jennifer Schneider; David Claman; Steven R Cummings Journal: Arch Intern Med Date: 2008-09-08
Authors: Jennifer S Albrecht; Emerson M Wickwire; Aparna Vadlamani; Steven M Scharf; Sarah E Tom Journal: Am J Geriatr Psychiatry Date: 2018-11-02 Impact factor: 4.105
Authors: Christine M Swanson; Wendy M Kohrt; Orfeu M Buxton; Carol A Everson; Kenneth P Wright; Eric S Orwoll; Steven A Shea Journal: Metabolism Date: 2017-12-09 Impact factor: 8.694
Authors: Emerson M Wickwire; Aparna Vadlamani; Sarah E Tom; Abree M Johnson; Steven M Scharf; Jennifer S Albrecht Journal: Sleep Date: 2020-01-13 Impact factor: 5.849
Authors: Thomas C Neylan; Anne Richards; Thomas J Metzler; Leslie M Ruoff; Jonathan Varbel; Aoife O'Donovan; Melinda Sivasubramanian; Terri Motraghi; Jennifer Hlavin; Steven L Batki; Sabra S Inslicht; Kristin Samuelson; Stephen R Morairty; Thomas S Kilduff Journal: Sleep Date: 2020-10-13 Impact factor: 5.849
Authors: Hyungjin Myra Kim; Lauren B Gerlach; Matheos Yosef; Claire Stano; Deirdre A Conroy; Marcia Valenstein; Paul N Pfeiffer; Anne E Sales; Kara Zivin Journal: J Clin Sleep Med Date: 2018-07-15 Impact factor: 4.062